DRG Market Assessment reports

Approximately 80% of rare diseases have a genetic etiology. Gene therapies hold the potential to transform the treatment of rare diseases and may provide a functional cure for some. However, these…

The 2016 and 2017 FDA approvals of multiple immune checkpoint inhibitors for advanced bladder cancer have greatly altered the treatment landscape for this disease. The FDA’s (2020) and EC’s (…

Dyslipidemia is an important modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD), a leading causes of death globally. Statins continue to dominate treatment for dyslipidemia,…

NASH has the potential to be a large and lucrative therapy market owing to the disease’s prevalence and the lack of approved agents. Patients with NASH are at risk of liver fibrosis,…

Multiple myeloma is an incurable hematological malignancy with a 100% mortality rate that affects a sizable portion of the Chinese population every year. With the introduction of proteasome…

Systemic lupus erythematosus (SLE) is a complex autoimmune disease that can affect nearly any organ or system in the body. As a result, its course, manifestations, and treatment approach can be…

The rising rates of antimicrobial resistance have created an urgent need for antibiotics with activity against drug-resistant gram-negative pathogens (GNPs). Antibiotics such as carbapenems, which…

The type 2 diabetes (T2D) therapy market will expand over the first half of the 2020-2030 forecast period. This increase will partly be fueled by a rich pipeline of novel agents, including emerging…

With an increasing prevalence due to aging populations, the major-market osteoporosis patient pool is large and growing. The combined influence of increased patient numbers and drug launches will…

Diabetic nephropathy (DN), also referred to as diabetic kidney disease, is a common complication of diabetes. The current standard of care fails to halt the frequent progression of DN to kidney…

The multiple myeloma therapy market continues to grow, fueled by the disease’s increasing incidence and long treatment durations. The availability of premium-priced branded agents prescribed in…

Peripheral arterial disease (PAD) is a common manifestation of systemic atherosclerosis that most often affects the arteries in the lower extremities. This condition is a major marker for more-…